

Reviewer Relationships with Industry and Other Entities (Comprehensive) — 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Vanita Aroda	Brigham and Women’s Hospital, Harvard Medical School—Director, Diabetes Clinical Research, Division of Endocrinology, Diabetes and Hypertension, Department of Medicine	Applied Therapeutics; Duke University School of Medicine (s); Liberum; Novo Nordisk (s); Sanofi-Aventis (s)	None	None	None	Fractyl/Premier‡ Merck (s)	None
George L. Bakris	University of Chicago Medicine—Professor of Medicine; Director, Hypertensive Diseases Unit	Merck	None	None	Bayer; Janssen; Relypsa; Vascular Dynamics	Novo Nordisk (s)	None
Nicole M. Bhave	University of Michigan—Assistant Professor of Cardiovascular Medicine	None	None	None	None	None	None
Roger S. Blumenthal	Johns Hopkins Hospital—Pollin Professor of Cardiology	None	None	None	None	None	None
John B. Buse	University of North Carolina School of Medicine—Director, Diabetes Care	Cirius Therapeutics; Neurimmune (n)	None	Mellitus Health; Pendulum; PhaseBio; Stability Health	NovaTarg; Novo Nordisk (s); Sanofi-Aventis (s); Tolerion (s);	Adocia (n); AstraZeneca (n); Dance Biopharm (n); Eli Lilly (n); MannKind (n); NovaTarg (n);	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
					vTv Therapeutics (s)	Novo Nordisk (n); Senseonics (n); vTv Therapeutics (n); Zafgen (n)	
Matthew A. Cavender	University of North Carolina, Chapel Hill—Assistant Professor of Medicine, Interventional Cardiology	AstraZeneca (s); Boehringer-Ingelheim (s); Edwards Lifesciences; Merck (s); Novo Nordisk (s)	None	None	AstraZeneca (n); Bristol Myers Squibb (n); Chiesi (n); CSL Behring (n); Novartis (n)	St. Jude‡	None
Deborah S. Croy	Bland County Medical Clinic, Virginia—Adult Nurse Practitioner	None	None	None	None	None	None
Prakash C. Deedwania	University of California San Francisco—Chief of Cardiology	Janssen (s); Pfizer; Sanofi-Aventis (s)	None	None	None	Boehringer Ingelheim‡ Novartis‡ Sanofi-Aventis‡	None
Gregory J. Dehmer	Virginia Tech Carilion School of Medicine; Carilion Clinic, Cardiology and Carilion Cardiovascular Institute—Medical Director, Quality and Outcomes	CMS MedCAC Panel; FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee	None	None	None	SCAI (n)	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Boris Draznin	University of Colorado Denver, School of Medicine—Director, Adult Diabetes Program, Celeste and Jack Grynberg Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes	None	None	None	None	None	None
James M. Falko	University of Colorado Lone Tree Medical Center—Clinical Professor of Medicine	Merck	Merck	None	None	None	None
Jennifer Green	Duke University Medical Center—Professor of Medicine, Department of Medicine, Division of Endocrinology	AstraZeneca; Boehringer Ingelheim (s)	None	None	Boehringer Ingelheim (s); Novo Nordisk (DSMB) Sanofi-Aventis (s)	ADA (s); The Endocrine Society (s)	None
Martha Gulati	University of Arizona College of Medicine—Chief of Cardiology	None	None	None	None	None	None
Stuart T. Haines	University of Mississippi School of Pharmacy—Professor and Director, Pharmacy Professional Development	None	None	Rx Instructional Systems (s)	None	AACP (n)	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Joshua J. Joseph	The Ohio State University Wexner Medical Center—Assistant Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism; Investigator, Diabetes and Metabolism Research Center; Affiliated Faculty, Translational Data Analytics Institute	None	None	None	None	None	None
Cynthia A. Lamendola	Stanford University School of Medicine—Nurse Practitioner and Clinical Research Nurse Coordinator	None	None	None	Eiger Biopharmaceuticals (s)	Eiger Biopharmaceuticals‡ Janssen‡	None
Shahar Lavi	Western University London Health Sciences Centre—Associate Professor; Director of Cardiovascular Interventional Research, Division of Cardiology, Department of Medicine	Bayer Healthcare; Biosensors	None	None	None	None	None
Joanna Mitri	Harvard Medical School—Research Associate, Section on Clinical, Behavioral, and Outcomes Research Lipid Clinic, Adult	Cutheath (n); Local dairy farmers (s); National Dairy Council; Novo Nordisk (s)	None	None	Kowa (n); National Dairy Council (n)	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Guillermo E. Umpierrez	Emory University— Professor of Medicine; Grady Health System— Section Head, Diabetes and Endocrinology	None	None	None	None	None	None
Deborah Wexler	Massachusetts General Hospital (MGH)— Associate Clinical Chief, MGH Diabetes Unit; Clinical Director, MGH Diabetes Center	None	None	None	Novo Nordisk (DSMB)	None	None
Veronica Wilbur	West Chester University, West Chester Pennsylvania—Assistant Professor; Next Century Medical Care, Wilmington Delaware—Family Nurse Practitioner	None	None	None	None	None	None
David E. Winchester	University of Florida College of Medicine (UFCOM)—Associate Professor of Medicine; Malcom Randall VAMC— Staff Cardiologist; Assistant Cardiology Fellowship Program Director, Quality and Research; Co-Director, Advanced Fellowship for	None	None	None	None	Alachua County Medical Society Board of Directors (n)	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Research/Research Grants	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Cardiovascular Imaging; Co-Director, University of Florida (UF) Health Cardiac Imaging Group						
Nathan D. Wong	University of California, Irvine—Professor and Director, UCI Heart Disease Prevention Program	Amarin (s); Esperion (s); Sanofi	None	None	Amarin (s); Amgen (s); Boehringer Ingelheim (s); Novartis (s); Novo Nordisk (s)	None	None
Eugene Yang	University of Washington School of Medicine—Clinical Professor of Medicine, Division of Cardiology, Carl and Renée Behnke Endowed Professorship for Asian Health; UW Medicine Eastside Specialty Center—Medical Director; Co-Director, Cardiovascular Wellness and Prevention Program	None	None	Clocktree	Amgen (s)	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of

≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

(s) Significant relationship.

(n) No financial benefit.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

AACP=American Association of Colleges of Pharmacy; ADA=American Diabetes Association; CMS=Centers for Medicare and Medicaid Services; DSMB=Data Safety Monitoring Board; FDA=United States Food and Drug Administration; MedCAC=The Medicare Evidence Development and Coverage Advisory Committee; NIH=National Institutes of Health; SCAI=Society for Cardiac Angiography and Interventions; UW=University of Washington; VA=Veterans Administration; VAMC=Veterans Administration Medical Center.